Tag Archives: PUBLIC BIOTECH – Stats

Many Biotechs Still Operating at Low Cash Levels

The percentage of public biotech companies that still operate with less than a year of cash is at 38% (see chart).  Given that we already lost a number of companies in 2009 due to lack of cash to fund research, this is a high percentage for the remaining companies. This is even more interesting when you consider that 2009 was a big year for Follow-On Offerings (FOPOs) and Private Investments in Public Equity (PIPEs). The Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: ,

Fewer Public Biotechs in 2010 vs 2008

Back in January 2008, we were tracking 394 “active” public biotech companies. (By “active”, we mean companies that are filing with the SEC and not in bankruptcy or in a major restructuring due financial distress.) As of January 2010, we have 295 – a loss of ~25%. About 48% of the companies that are no longer “active” have been acquired and 52% have gone out of business, filed bankruptcy, or are no longer filing with Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: ,

Sector Performance Since the 2007 Market Peak

How does the biotech sector performance rank against the 10 S&P sectors since the S&P500 peak back on October 9th, 2007? As of January 6th, 2010, the Nasdaq Biotech Index (NBI) outperformed all 10 sectors, including the overall healthcare sector and the other traditionally defensive sectors: utilities and consumer staples. The AMEX Biotech Index (BTK) had some unique events in 2009 that helped it not only outperform every sector, but remain in double digit positive Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: ,

Small Biotechs Spending Less

The median and mean operational cash spending for small public US biotechs (less than 250 employees) is down 37% and 42% respectively, since the 1st Quarter of 2008. Company cut backs have shown up in the lay-off numbers as well as in the number of drug development projects put on hold. These quarterly numbers give a sense of the direction. For a look at the annual data, here is how spending breaks down for the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

1 in 4 Biotechs Above 100% – Waterfall Chart YTD

Year to date,  27% of biotech stocks have doubled in price. 65% are in positive territory in 2009, a strong contrast to the YTD data last year:

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,